News and Announcements
Blue Sky Biologicals Announces High Volume Manufacturing Agreement
- Published November 10, 2017 12:00AM UTC
- Publisher Wholesale Investor
- Categories Company Updates
KEY TAKEAWAYS:
- Blue Sky Biologicals will produce a CBD based pain relief product for Soverign Funds Pty Ltd for the Australian Pharmaceutical marketplace.
- Marks one of the largest CBD production agreements in Australia
- Sovereign to market the Blue Sky manufactured product globally.
Vancouver, BC, November 8, 2017 – Blue Sky Biologicals Inc. (“BlueSky”) is pleased to announce that it has signed a Heads of Agreement (“HOA”) with Sovereign Funds Pty. Ltd. (“Sovereign”) of New South Wales, Australia for the production of Sovereign’s proprietary pain relief formulation.
With its GMP standard processing facility and the largest cannabidiol (CBD) and cannabinoid production capacity in the world, BlueSky will meet the rigorous specifications set by Sovereign while also fulfilling the volumes required.
“We are very pleased to be able to work with Sovereign to produce and supply their groundbreaking, CBD-based pain relief formula, CannadeineTM. Blue Sky Biologicals will continue to provide a completely organic and sustainable supply of industrial hemp-based CBD formulations to Sovereign to match their market growth” said Wade Hobson, Executive Vice President of BlueSky, managing the Asia Pacific region.
“Sovereign will now have the ability to distribute large volumes of their innovative pain relief products through a regulated pharmacy program, marking a milestone in the Australian medicinal marketplace, in compliance with the stringent Australian regulatory regime now in place for import and production” said Hobson.
About BlueSky
BlueSky is a vertically integrated global leader in CBD’s produced from its organic, hand harvested industrial hemp fields. BlueSky manufactures its CBD’s without the use of hexane or propylene glycol, maintaining high levels of purity through the entire product portfolio. BlueSky provides a full range of products within the four categories of Dietary Supplements, Personal Care, Functional Foods/Beverages and an exclusive Pet Care line.
About Sovereign
Sovereign is a producer of CBD and cannabinoid medicines. Sovereign is the proprietor of CannadolTM and CannadeineTM, which are the worldwide trademarks of their CBD medicine that derives from a stable breed and has a unique combination of cannabinoids for pain relief as well as prompt beneficial relief of many conditions and serious ailments.
Company Updates
Dogs First to Reduce Risk: QBiotics’ Smarter Path to Oncology Markets
QBiotics took a compound derived from a north Queensland rainforest tree all the way to veterinary registration before pursuing human oncology to de-risk its human cancer programme. Interim CEO Ebru Davidson argues that sequence – now backed by early responses across several human cancers – is the company’s real asset. The story that pulled Wholesale […]
Built on discipline, not complexity: inside an ASX equities income strategy
Haydn Froggatt and Zac Brabin have decades of derivatives experience between them and access to almost any strategy in the market. They use two of the simplest structures available, and wrote 202 positions with them last year. Published by Fairway Capital Management. Based on an interview with co-founders Haydn Froggatt and Zac Brabin. Two traders, […]
BlackRock has named the next Economy. What this latest paper means for Private Market Investors.
BlackRock has put a name on something the smart money has been circling for two years. Its digital assets research team calls it the machine-native economy. The thesis fits in one line. AI is machine-native intelligence. Digital assets are machine-native money. Both are built on the same architecture, and they are converging into a single […]
Backed By Leading Investment Groups and Family Offices
